Trial Profile
A Multi-Center Study of the Safety, Tolerability, Pharmacokinetics, and Dose Escalation of Intravenous Recombinant Human Mannose-Binding-Lectin (rhMBL) in MBL Deficient Pediatric Haematology/Oncology Patients With Fever and Neutropenia
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Mannose binding lectin (Primary)
- Indications Infections
- Focus Adverse reactions
- Sponsors Enzon Pharmaceuticals
- 18 Sep 2014 New trial record